Lineage Q2 net loss narrows to $5.2M; OpRegen phase 2a enrolling, OPC1 IND plan in Q4

Lineage Cell Therapeutics, Inc.

2023-Q2 EPS reported -$0.06 revenue$5,611,000

Net loss narrowed to $5.2M ($0.03/shr) from $6.8M ($0.04/shr) in Q2 2022.
Revenue fell to $3.2M from $4.6M YoY, driven by lower Roche collaboration revenue.
Cash $45.9M; expected to fund operations into Q4 2024.
OpRegen Phase 2a enrolling; FDA meeting response enables OPC1 delivery device IND amendment in Q4.
VAC2 Phase 1 topline: five of eight stable disease; three of eight reached 2-year survival.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Lineage Cell Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $3.2 million.

Period: second quarter ended June 30, 2023
Revenue: $3.2 million
Result: reported results

Exact text from the filing

revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended June 30, 2023 were $3.2 million, a net decrease of $1.4 million as compared to approximately $4.6 million for the same period in 2022. The decrease was primarily driven by less collaboration and licensing

View on SEC.gov

Browse all earnings releases →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027545

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.